Press release
Herpes Zoster Treatment Market Size in the 7MM is projected to increase at a significantly CAGR by 2036, estimates DelveInsight
Discover Key Insights into the Herpes Zoster Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/herpes-zoster-market [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Herpes Zoster Market Report
* In March 2026- Sinovac (Dalian) Vaccine Technology Co., Ltd. initiated a study aim to assess the immunogenicity and safety of interchangeable administration of the second dose of varicella vaccine. A total of 300 healthy participants aged 15 months - 12 years will be enrolled. Written informed consent form will be obtained from participants' parents or legally acceptable representatives (and assents will be obtained from participants aged above 9 years old and written consent forms will be prepared and consent will be obtained in writing if possible from the participants aged 3-8 years old.) before enrollment.
* In March 2026- MAXVAX Biotechnology Limited Liability Company announced a phase III study is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete immunization with the 0- and 2-month immunization schedule in individuals aged 40 years and older.
* On January 07, 2026- Pfizer announced a clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV modRNA). We are seeking for healthy participants 50 through 85 years of age.
* On January 07, 2026- Shanghai Institute Of Biological Products conducted a clinical study is to evaluate the safety and immunogenicity of receiving two doses of recombinant herpes zoster vaccine (CHO cells) (RHZV) in healthy individuals aged 40 years and above. This study will be conducted in 2 substudies: Substudy A (Phase I) and Substudy B (Phase ).
* According to analysis, approximately one in every three individuals residing in the United States will experience an episode of shingles, medically referred to as herpes zoster, during their lifetime. It is estimated that around one million individuals are affected by shingles annually within the country.
* Based on our secondary analysis, in Japan the herpes zoster prevalence among individuals in the general population aged 50 years and above is approximately 10 per 1000 person-years (PY), with a higher prevalence observed among those aged 60 years and above. Moreover, the incidence escalates to more than 12 per 1000 PY in individuals aged 80 years and older.
* Among the 7MM, the lowest number of healthy patient population at-risk for herpes zoster was found to be in Spain.
* Assessments showed that among the European countries, Germany had the highest eligible patient population for herpes zoster vaccination and and are expected to increase by 2034.
* Elderly individuals and those with weakened immune systems, considered high-risk groups, may encounter cumulative incidences of up to 50%.
* The leading Herpes Zoster Companies such as Curevo Inc., Mogam Biotechnology Research Institute, Green Cross Corporation, Immoma Biotherapeutics Inc., Icon Plc, Pascoe Pharmazeutische Praeparate GmbH, GlaxoSmithKline, Astellas Pharma Inc., Yung Shin Pharm Ind. Co. Ltd., Jiangsu Rec-Biotechnology Co., Ltd., Maruho Co. Ltd., Epiphany Biosciences, EMS, Nobelpharma, Bristol-Myers Squibb, and others.
* Promising Herpes Zoster Therapies such as JCXH-105, TNM005, CRV-101 Vaccine Antigen High Dose, mRNA-1468, PF-07915234, HZ/su vaccine, Herpes Zoster Vaccine GSK1437173A, Varicella Zoster Vaccine, and others
Stay ahead in the Herpes Zoster Therapeutics Market with DelveInsight's Strategic Report @ Herpes Zoster Market Outlook [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Herpes Zoster Epidemiology Segmentation in the 7MM
* Total Healthy Patient Population at-risk for Herpes Zoster
* Eligible Patient Population for Herpes Zoster Vaccination
Download the report to understand which factors are driving Herpes Zoster Epidemiology trends @ Herpes Zoster Prevalence [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Marketed Herpes Zoster Therapies
* Shingrix : GlaxoSmithKline (GSK)
Shingrix (herpes zoster vaccine recombinant, adjuvant), also known as GSK1437173A is a non-live, recombinant subunit vaccine that help prevent Herpes Zoster (herpes zoster) in adults 50 years of age and older. The vaccine combines an antigen, glycoprotein E, and an adjuvant system, AS01B, intended to generate a strong and long-lasting immune response that can help overcome the decline in immunity that occurs as people age. Shingrix is given intramuscularly in two doses. Shingrix is currently licensed for use in the EU, US, Canada, Japan, China, and Australia.
Emerging Herpes Zoster Therapies
* CRV-101: Curevo Inc.
CRV-101 is an investigational adjuvanted subunit vaccine under investigation for the prevention of Herpes Zoster in older adults. CRV-101 was specifically designed to produce an optimal immune response while using a smaller amount of adjuvant with the intention of achieving similar efficacy but with fewer side effects than the currently-approved Herpes Zoster vaccine. On September 2022, Curevo announced completion of enrollment in a Phase IIb trial of their CRV-101 subunit vaccine to prevent the reactivation of the varicella zoster virus (shingles) in older adults.
To know more about Herpes Zoster treatment guidelines, visit @ Herpes Zoster Treatment Market Landscape [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Herpes Zoster Therapies and Companies
* JCXH-105: Immorna Biotherapeutics, Inc./ICON plc
* TNM005: Zhuhai Trinomab Pharmaceutical Co., Ltd.
* CRV-101 Vaccine Antigen High Dose: Curevo Inc/Green Cross Corporation
* mRNA-1468: ModernaTX, Inc.
* PF-07915234: Pfizer
* HZ/su vaccine: GlaxoSmithKline
* Herpes Zoster Vaccine GSK1437173A: GlaxoSmithKline
* Varicella Zoster Vaccine: Bristol-Myers Squibb
Herpes Zoster Market Dynamics
The herpes zoster market dynamics have undergone significant changes over the years. Firstly, the aging population is a significant driver. As the global population continues to age, the risk of developing herpes zoster increases, creating a growing patient pool for antiviral medications and vaccines. Additionally, advancements in medical research and development have brought new treatments and vaccines to the market. Vaccination campaigns, such as the introduction of the varicella-zoster vaccine, have helped reduce the incidence and severity of herpes zoster. This, in turn, affects the demand for antiviral medications and preventive treatments.
Learn more about the FDA-approved drugs for Herpes Zoster @ Drugs for Herpes Zoster Treatment [https://www.delveinsight.com/sample-request/herpes-zoster-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Herpes Zoster Market Report
- Coverage- 7MM
- Study Period- 2022-2036
- Herpes Zoster Companies- Immorna Biotherapeutics, Inc., ICON plc, Zhuhai Trinomab Pharmaceutical Co., Ltd., Curevo Inc, Green Cross Corporation, ModernaTX, Inc., Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, and others
- Herpes Zoster Therapies- JCXH-105, TNM005, CRV-101 Vaccine Antigen High Dose, mRNA-1468, PF-07915234, HZ/su vaccine, Herpes Zoster Vaccine GSK1437173A, Varicella Zoster Vaccine, and others
- Herpes Zoster Unmet Needs, KOL's views, Analyst's views, Herpes Zoster Market Access and Reimbursement
Table of Contents
1. Key Insights
2. Report Introduction
3. Herpes Zoster (Shingles) Market Overview at a Glance
4. Herpes Zoster Epidemiology and Market Methodology
5. Herpes Zoster Executive Summary
6. Key Events
7. Herpes Zoster Disease Background and Overview
8. Herpes Zoster Epidemiology and Patient Population
9. Herpes Zoster Patient Journey
10. Herpes Zoster Marketed Products
11. Herpes Zoster Emerging Treatment and Management
12. Herpes Zoster: 7 Major Market Analysis
13. Herpes Zoster SWOT Analysis
14. Herpes Zoster KOL Views
15. Herpes Zoster Unmet Needs
16. Herpes Zoster Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=herpes-zoster-treatment-market-size-in-the-7mm-is-projected-to-increase-at-a-significantly-cagr-by-2036-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Herpes Zoster Treatment Market Size in the 7MM is projected to increase at a significantly CAGR by 2036, estimates DelveInsight here
News-ID: 4458873 • Views: …
More Releases from ABNewswire
Human Papillomavirus-positive Oropharyngeal Cancer Clinical Trial Pipeline Expan …
DelveInsight's, "Human Papillomavirus-positive Oropharyngeal Cancer Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Human Papillomavirus-positive Oropharyngeal Cancer pipeline landscape. It covers the Human Papillomavirus-positive Oropharyngeal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Human Papillomavirus-positive Oropharyngeal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products…
Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorousl …
DelveInsight's "Influenza Pipeline Insight 2026" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Influenza pipeline landscape. It covers the Influenza Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Influenza Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Influenza Pipeline?…
Hepatitis B Virus Infection Clinical Trial Pipeline Gains Momentum: 80+ Companie …
DelveInsight's, "Hepatitis B Virus Infection Pipeline Insight 2026" report provides comprehensive insights about 80+ companies and 90+ pipeline drugs in Hepatitis B Virus (HBV) Infection pipeline landscape. It covers the Hepatitis B Virus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatitis B Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
Must-Read for Bonsai Enthusiasts: How to Choose a Small Electric Pruning Shear?
For lovers of bonsai art, a handy electric pruning shear is just as essential as a paintbrush is to a painter. Traditional manual pruning shears are not only labor-intensive when cutting slightly thick branches but also prone to damaging plants due to uneven cutting surfaces. In recent years, small electric pruning shears have gradually become a new favorite among many seasoned bonsai lovers for their advantages of being labor-saving and…
More Releases for Zoster
Innovations and Growth in the Herpes Zoster Ophthalmicus Drug Market
Herpes Zoster Ophthalmicus (HZO) presents a significant clinical challenge, with the varicella-zoster virus reactivating in the ophthalmic division of the trigeminal nerve to cause painful, vision-threatening complications. Over the past decade, heightened awareness of HZO's potential to cause chronic ocular inflammation, corneal scarring, and vision loss has driven robust investment in both antiviral and adjunctive therapies. As patient populations continue to age and the prevalence of immunocompromising conditions rises globally,…
Herpes Zoster Pipeline Therapeutics Assessment 2024 (Updated)
DelveInsight's, "Herpes Zoster Pipeline Insight 2024," report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Herpes Zoster pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Herpes Zoster Research. Learn more…
Herpes Zoster Treatment Market Analysis and Future Prospects for 2030
The world of the herpes zoster treatment market is a complex and ever-evolving landscape, shaped by consumer demands and technological advancements. In this report, we delve into the depths of this market to provide a profound and comprehensive analysis, catering to a diverse audience that includes manufacturers, suppliers, distributors, and investors. Our primary goal is to empower industry stakeholders with invaluable insights to make informed decisions in a rapidly changing…
Zoster Vaccine Live Market | GSK, Merck, ,
The global zoster vaccine live market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the zoster vaccine live market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
Herpes Zoster Market Share, Size, Insights, Trends, and Forecast 2032
A detailed review of the historical and forecasted Herpes Zoster market is included in the report, covering drug outreach in the 7MM countries. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Herpes Zoster market.
Herpes Zoster: An Overview
Herpes zoster (HZ), also called Shingles, is a neurocutaneous disease that is generally caused by the reactivation of varicella-zoster virus (VZV) from a latent…
Zoster Vaccine Live Market global outlook and forecast 2021 -2027
The Global Zoster Vaccine Live Market research report is a careful examination of the worldwide industry which has been a region of enthusiasm for a Zoster Vaccine Live makers, organizations, authorities, chiefs, and likely speculators, and analysts. The report profoundly lights up noteworthy features in the business, including a contention situation, condition, portions, showcase size, share, gainfulness, development potential, and advancements.
The report likewise…
